终末期肾病患者使用促红细胞生成素是否有害？

Is there a deleterious effect of erythropoietin in end-stage renal disease?

机构信息

Renal Division, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

出版信息

Kidney Int. 2011 Sep;80(6):569-71. doi: 10.1038/ki.2011.190.

DOI:10.1038/ki.2011.190

Abstract

The use of erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease has declined as randomized controlled trials have demonstrated increased risk of cardiovascular complications and mortality without a marked benefit in quality of life. Several studies have suggested that exposure to high dosages of ESA, rather than raising of the hemoglobin concentration, explains this increased risk. Cotter and colleagues report that exposure to high dosages of ESA in patients with diabetes is associated with increased risk.

摘要

促红细胞生成素刺激剂（ESAs）在慢性肾脏病患者中的使用已经减少，因为随机对照试验表明心血管并发症和死亡率的风险增加，而生活质量没有明显改善。一些研究表明，高剂量 ESA 的暴露，而不是血红蛋白浓度的升高，解释了这种风险的增加。Cotter 及其同事报告称，糖尿病患者高剂量 ESA 的暴露与风险增加有关。